Our data may provide rationale for the mechanistic investigation of the combination of ICI with EGFR inhibition in tumours with EGFR CNG as a means to enhance anticancer immune responses and improve the efficacy of immunotherapies. The gene discussed is EGFR; the disease is neoplasm.